1932

Abstract

Postural orthostatic tachycardia syndrome (POTS) is a clinically heterogeneous disorder with multiple contributing pathophysiologic mechanisms manifesting as symptoms of orthostatic intolerance in the setting of orthostatic tachycardia (increase in heart rate by at least 30 beats per minute upon assuming an upright position) without orthostatic hypotension. The three major pathophysiologic mechanisms include partial autonomic neuropathy, hypovolemia, and hyperadrenergic state. Patients often will exhibit overlapping characteristics from more than one of these mechanisms. The approach to the treatment of POTS centers on treating the underlying pathophysiologic mechanism. Stockings, abdominal binders, and vasoconstrictors are used to enhance venous return in partial neuropathic POTS. Exercise and volume expansion are the main treatment strategies for hypo-volemic POTS. For hyperadrenergic POTS, beta-blockers and avoidance of norepinephrine reuptake inhibitors is important. Attempts should be made to discern which pathophysiologic mechanism(s) may be afflicting patients so that treatment regimens can be individualized.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-041818-011630
2020-01-27
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/med/71/1/annurev-med-041818-011630.html?itemId=/content/journals/10.1146/annurev-med-041818-011630&mimeType=html&fmt=ahah

Literature Cited

  1. 1. 
    Low PA, Opfer-Gehrking TL, Textor SC et al. 1995. Postural tachycardia syndrome (POTS). Neurology 45:S19–S25
    [Google Scholar]
  2. 2. 
    Shaw BH, Stiles LE, Bourne K et al. 2019. The face of postural tachycardia syndrome—insights from a large cross-sectional online community-based survey. J. Intern. Med. 286:438–48
    [Google Scholar]
  3. 3. 
    Raj SR. 2013. Postural tachycardia syndrome (POTS). Circulation 127:2336–42
    [Google Scholar]
  4. 4. 
    Raj SR, Robertson D. 2018. Moving from the present to the future of postural tachycardia syndrome—what we need. Auton. Neurosci. 215:126–28
    [Google Scholar]
  5. 5. 
    Robertson D. 1999. The epidemic of orthostatic tachycardia and orthostatic intolerance. Am. J. Med. Sci. 317:75–77
    [Google Scholar]
  6. 6. 
    Streeten DH, Anderson GH Jr, Richardson R, Thomas FD 1988. Abnormal orthostatic changes in blood pressure and heart rate in subjects with intact sympathetic nervous function: evidence for excessive venous pooling. J. Lab. Clin. Med. 111:326–35
    [Google Scholar]
  7. 7. 
    Masuki S, Eisenach JH, Johnson CP et al. 2007. Excessive heart rate response to orthostatic stress in postural tachycardia syndrome is not caused by anxiety. J. Appl. Physiol. 102:896–903
    [Google Scholar]
  8. 8. 
    Mar PL, Raj SR. 2014. Neuronal and hormonal perturbations in postural tachycardia syndrome. Front. Physiol. 5:220
    [Google Scholar]
  9. 9. 
    Shibao C, Arzubiaga C, Roberts LJ 2nd et al. 2005. Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders. Hypertension 45:385–90
    [Google Scholar]
  10. 10. 
    Miglis MG, Schultz B, Muppidi S 2017. Postural tachycardia in hypermobile Ehlers-Danlos syndrome: a distinct subtype?. Auton. Neurosci. 208:146–49
    [Google Scholar]
  11. 11. 
    Roma M, Marden CL, De Wandele I et al. 2018. Postural tachycardia syndrome and other forms of orthostatic intolerance in Ehlers-Danlos syndrome. Auton. Neurosci. 215:89–96
    [Google Scholar]
  12. 12. 
    Parsaik A, Allison TG, Singer W et al. 2012. Deconditioning in patients with orthostatic intolerance. Neurology 79:1435–39
    [Google Scholar]
  13. 13. 
    Shannon JR, Flattem NL, Jordan J et al. 2000. Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N. Engl. J. Med. 342:541–49
    [Google Scholar]
  14. 14. 
    Stewart JM. 2002. Pooling in chronic orthostatic intolerance: arterial vasoconstrictive but not venous compliance defects. Circulation 105:2274–81
    [Google Scholar]
  15. 15. 
    Stewart JM, Medow MS, Montgomery LD 2003. Local vascular responses affecting blood flow in postural tachycardia syndrome. Am. J. Physiol. Heart Circ. Physiol. 285:H2749–56
    [Google Scholar]
  16. 16. 
    Stewart JM, Weldon A. 2000. Vascular perturbations in the chronic orthostatic intolerance of the postural orthostatic tachycardia syndrome. J. Appl. Physiol. 89:1505–12
    [Google Scholar]
  17. 17. 
    Stewart JM, Weldon A. 2001. Reflex vascular defects in the orthostatic tachycardia syndrome of adolescents. J. Appl. Physiol. 90:2025–32
    [Google Scholar]
  18. 18. 
    Jacob G, Costa F, Shannon JR et al. 2000. The neuropathic postural tachycardia syndrome. N. Engl. J. Med. 343:1008–14
    [Google Scholar]
  19. 19. 
    Streeten DH 1990. Pathogenesis of hyperadrenergic orthostatic hypotension. Evidence of disordered venous innervation exclusively in the lower limbs. J. Clin. Investig. 86:1582–88
    [Google Scholar]
  20. 20. 
    Diedrich A, Biaggioni I. 2004. Segmental orthostatic fluid shifts. Clin. Auton. Res. 14:146–47
    [Google Scholar]
  21. 21. 
    Stewart JM, Medow MS, Glover JL, Montgomery LD 2006. Persistent splanchnic hyperemia during upright tilt in postural tachycardia syndrome. Am. J. Physiol. Heart Circ. Physiol. 290:H665–73
    [Google Scholar]
  22. 22. 
    Stewart JM, Montgomery LD. 2004. Regional blood volume and peripheral blood flow in postural tachycardia syndrome. Am. J. Physiol. Heart Circ. Physiol. 287:H1319–27
    [Google Scholar]
  23. 23. 
    Stewart JM, Pianosi P, Shaban MA et al. 2018. Postural hyperventilation as a cause of postural tachycardia syndrome: increased systemic vascular resistance and decreased cardiac output when upright in all postural tachycardia syndrome variants. J. Am. Heart Assoc. 7:1–11
    [Google Scholar]
  24. 24. 
    Tani H, Singer W, McPhee BR et al. 2000. Splanchnic-mesenteric capacitance bed in the postural tachycardia syndrome (POTS). Auton. Neurosci. 86:107–13
    [Google Scholar]
  25. 25. 
    Del Pozzi AT, Pandey A, Medow MS et al. 2014. Blunted cerebral blood flow velocity in response to a nitric oxide donor in postural tachycardia syndrome. Am. J. Physiol. Heart Circ. Physiol 307:H397–404
    [Google Scholar]
  26. 26. 
    Jordan J, Shannon JR, Black BK et al. 1998. Raised cerebrovascular resistance in idiopathic orthostatic intolerance: evidence for sympathetic vasoconstriction. Hypertension 32:699–704
    [Google Scholar]
  27. 27. 
    Ocon AJ, Medow MS, Taneja I et al. 2009. Decreased upright cerebral blood flow and cerebral autoregulation in normocapnic postural tachycardia syndrome. Am. J. Physiol. Heart Circ. Physiol. 297:H664–73
    [Google Scholar]
  28. 28. 
    Medow MS, Minson CT, Stewart JM 2005. Decreased microvascular nitric oxide-dependent vasodilation in postural tachycardia syndrome. Circulation 112:2611–18
    [Google Scholar]
  29. 29. 
    Stewart JM, Medow MS, Minson CT, Taneja I 2007. Cutaneous neuronal nitric oxide is specifically decreased in postural tachycardia syndrome. Am. J. Physiol. Heart Circ. Physiol. 293:H2161–67
    [Google Scholar]
  30. 30. 
    De Wandele I, Rombaut L, Leybaert L et al. 2014. Dysautonomia and its underlying mechanisms in the hypermobility type of Ehlers-Danlos syndrome. Semin. Arthritis Rheum. 44:93–100
    [Google Scholar]
  31. 31. 
    Doherty TA, White AA. 2018. Postural orthostatic tachycardia syndrome and the potential role of mast cell activation. Auton. Neurosci. 215:83–88
    [Google Scholar]
  32. 32. 
    Li H, Yu X, Liles C et al. 2014. Autoimmune basis for postural tachycardia syndrome. J. Am. Heart Assoc. 3:e000755
    [Google Scholar]
  33. 33. 
    Fu Q, VanGundy TB, Shibata S et al. 2010. Menstrual cycle affects renal-adrenal and hemodynamic responses during prolonged standing in the postural orthostatic tachycardia syndrome. Hypertension 56:82–90
    [Google Scholar]
  34. 34. 
    Raj SR, Biaggioni I, Yamhure PC et al. 2005. Renin-aldosterone paradox and perturbed blood volume regulation underlying postural tachycardia syndrome. Circulation 111:1574–82
    [Google Scholar]
  35. 35. 
    Stewart JM, Glover JL, Medow MS 2006. Increased plasma angiotensin II in postural tachycardia syndrome (POTS) is related to reduced blood flow and blood volume. Clin. Sci. (London) 110:255–63
    [Google Scholar]
  36. 36. 
    Mustafa HI, Garland EM, Biaggioni I et al. 2011. Abnormalities of angiotensin regulation in postural tachycardia syndrome. Heart Rhythm 8:422–28
    [Google Scholar]
  37. 37. 
    Zhang ZY, Qian LL, Wang RX 2017. Molecular mechanisms underlying renin-angiotensin-aldosterone system mediated regulation of BK channels. Front. Physiol. 8:698
    [Google Scholar]
  38. 38. 
    Mustafa HI, Raj SR, Diedrich A et al. 2012. Altered systemic hemodynamic and baroreflex response to angiotensin II in postural tachycardia syndrome. Circ. Arrhythm. Electrophysiol. 5:173–80
    [Google Scholar]
  39. 39. 
    Levine BD, Pawelczyk JA, Ertl AC et al. 2002. Human muscle sympathetic neural and haemodynamic responses to tilt following spaceflight. J. Physiol. 538:331–40
    [Google Scholar]
  40. 40. 
    Tank J, Baevsky RM, Funtova II et al. 2011. Orthostatic heart rate responses after prolonged space flights. Clin. Auton. Res. 21:121–24
    [Google Scholar]
  41. 41. 
    Levine BD, Zuckerman JH, Pawelczyk JA 1997. Cardiac atrophy after bed-rest deconditioning: a nonneural mechanism for orthostatic intolerance. Circulation 96:517–25
    [Google Scholar]
  42. 42. 
    Fu Q, VanGundy TB, Galbreath MM et al. 2010. Cardiac origins of the postural orthostatic tachycardia syndrome. J. Am. Coll. Cardiol. 55:2858–68
    [Google Scholar]
  43. 43. 
    Jacob G, Ertl AC, Shannon JR et al. 1998. Effect of standing on neurohumoral responses and plasma volume in healthy subjects. J. Appl. Physiol. 84:914–21
    [Google Scholar]
  44. 44. 
    Fedorowski A, Li H, Yu X et al. 2017. Antiadrenergic autoimmunity in postural tachycardia syndrome. Europace 19:1211–19
    [Google Scholar]
  45. 45. 
    Bayles R, Harikrishnan KN, Lambert E et al. 2012. Epigenetic modification of the norepinephrine transporter gene in postural tachycardia syndrome. Arterioscler. Thromb. Vasc. Biol. 32:1910–16
    [Google Scholar]
  46. 46. 
    Green EA, Raj V, Shibao CA et al. 2013. Effects of norepinephrine reuptake inhibition on postural tachycardia syndrome. J. Am. Heart Assoc. 2:e000395
    [Google Scholar]
  47. 47. 
    Mar PL, Raj V, Black BK et al. 2014. Acute hemodynamic effects of a selective serotonin reuptake inhibitor in postural tachycardia syndrome: a randomized, crossover trial. J. Psychopharmacol. 28:155–61
    [Google Scholar]
  48. 48. 
    Schroeder C, Tank J, Boschmann M et al. 2002. Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance. Circulation 105:347–53
    [Google Scholar]
  49. 49. 
    Vincent S, Bieck PR, Garland EM et al. 2004. Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles. Circulation 109:3202–7
    [Google Scholar]
  50. 50. 
    Garland EM, Celedonio JE, Raj SR 2015. Postural tachycardia syndrome: beyond orthostatic intolerance. Curr. Neurol. Neurosci. Rep. 15:60
    [Google Scholar]
  51. 51. 
    Fu Q, Levine BD. 2018. Exercise and non-pharmacological treatment of POTS. Auton. Neurosci. 215:20–27
    [Google Scholar]
  52. 52. 
    Dos Santos RQ, Smidt L, Suzigan BH et al. 2013. Efficacy of lower limb compression in the management of vasovagal syncope—randomized, crossover study. Pacing Clin. Electrophysiol. 36:451–55
    [Google Scholar]
  53. 53. 
    Okamoto LE, Diedrich A, Baudenbacher FJ et al. 2016. Efficacy of servo-controlled splanchnic venous compression in the treatment of orthostatic hypotension: a randomized comparison with midodrine. Hypertension 68:418–26
    [Google Scholar]
  54. 54. 
    Jacob G, Shannon JR, Black B et al. 1997. Effects of volume loading and pressor agents in idiopathic orthostatic tachycardia. Circulation 96:575–80
    [Google Scholar]
  55. 55. 
    Patel DP, Nair S, Suhagia BN, Patel BM 2016. A novel, sensitive and selective method of UPLC/MS-MS for rapid simultaneous determination of midodrine and its active metabolite desglymidodrine in human plasma: application to support bioequivalence study in healthy human volunteers. J. Pharm. Biomed. Anal. 131:355–63
    [Google Scholar]
  56. 56. 
    Ross AJ, Ocon AJ, Medow MS, Stewart JM 2014. A double-blind placebo-controlled cross-over study of the vascular effects of midodrine in neuropathic compared with hyperadrenergic postural tachycardia syndrome. Clin. Sci. (London) 126:289–96
    [Google Scholar]
  57. 57. 
    Wang H, Yang G, Zhou J et al. 2016. Development and validation of a UPLC-MS/MS method for quantitation of droxidopa in human plasma: application to a pharmacokinetic study. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 1027:234–38
    [Google Scholar]
  58. 58. 
    Ruzieh M, Dasa O, Pacenta A et al. 2017. Droxidopa in the treatment of postural orthostatic tachycardia syndrome. Am. J. Ther. 24:e157–e161
    [Google Scholar]
  59. 59. 
    Hoeldtke RD, Davis KM. 1991. The orthostatic tachycardia syndrome: evaluation of autonomic function and treatment with octreotide and ergot alkaloids. J. Clin. Endocrinol. Metab. 73:132–39
    [Google Scholar]
  60. 60. 
    Hunyady L, Catt KJ. 2006. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol. Endocrinol. 20:953–70
    [Google Scholar]
  61. 61. 
    Tuvia S, Atsmon J, Teichman SL et al. 2012. Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J. Clin. Endocrinol. Metab. 97:2362–69
    [Google Scholar]
  62. 62. 
    Galbreath MM, Shibata S, VanGundy TB et al. 2011. Effects of exercise training on arterial-cardiac baroreflex function in POTS. Clin. Auton. Res. 21:73–80
    [Google Scholar]
  63. 63. 
    George SA, Bivens TB, Howden EJ et al. 2016. The international POTS registry: evaluating the efficacy of an exercise training intervention in a community setting. Heart Rhythm 13:943–50
    [Google Scholar]
  64. 64. 
    Fu Q, VanGundy TB, Shibata S et al. 2011. Exercise training versus propranolol in the treatment of the postural orthostatic tachycardia syndrome. Hypertension 58:167–75
    [Google Scholar]
  65. 65. 
    Raj SR. 2016. Row, row, row your way to treating postural tachycardia syndrome. Heart Rhythm 13:951–52
    [Google Scholar]
  66. 66. 
    Raj S, Nwazue VC, Garland EM et al. 2014. The effect of dietary sodium on blood volume and heart rate in postural tachycardia syndrome. Heart Rhythm 11:S30
    [Google Scholar]
  67. 67. 
    Moak JP, Leong D, Fabian R et al. 2016. Intravenous hydration for management of medication-resistant orthostatic intolerance in the adolescent and young adult. Pediatr. Cardiol. 37:278–82
    [Google Scholar]
  68. 68. 
    Sheldon RS, Grubb BP 2nd, Olshansky B et al. 2015. 2015 Heart Rhythm Society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm 12:e41–e63
    [Google Scholar]
  69. 69. 
    Coffin ST, Black BK, Biaggioni I et al. 2012. Desmopressin acutely decreases tachycardia and improves symptoms in the postural tachycardia syndrome. Heart Rhythm 9:1484–90
    [Google Scholar]
  70. 70. 
    Miller AJ, Raj SR. 2018. Pharmacotherapy for postural tachycardia syndrome. Auton. Neurosci. 215:28–36
    [Google Scholar]
  71. 71. 
    Hoeldtke RD, Horvath GG, Bryner KD 1995. Treatment of orthostatic tachycardia with erythropoietin. Am. J. Med. 99:525–29
    [Google Scholar]
  72. 72. 
    Kanjwal K, Saeed B, Karabin B et al. 2012. Erythropoietin in the treatment of postural orthostatic tachycardia syndrome. Am. J. Ther. 19:92–95
    [Google Scholar]
  73. 73. 
    Zhao J, Tang C, Jin H, Du J 2014. Plasma copeptin and therapeutic effectiveness of midodrine hydrochloride on postural tachycardia syndrome in children. J. Pediatr 165:290–94.e1
    [Google Scholar]
  74. 74. 
    Anderson JW, Lambert EA, Sari CI et al. 2014. Cognitive function, health-related quality of life, and symptoms of depression and anxiety sensitivity are impaired in patients with the postural orthostatic tachycardia syndrome (POTS). Front. Physiol. 5:230
    [Google Scholar]
  75. 75. 
    Raj V, Haman KL, Raj SR et al. 2009. Psychiatric profile and attention deficits in postural tachycardia syndrome. J. Neurol. Neurosurg. Psychiatry 80:339–44
    [Google Scholar]
  76. 76. 
    Freitas J, Santos R, Azevedo E et al. 2000. Clinical improvement in patients with orthostatic intolerance after treatment with bisoprolol and fludrocortisone. Clin. Auton. Res. 10:293–99
    [Google Scholar]
  77. 77. 
    Moon J, Kim DY, Lee WJ et al. 2018. Efficacy of propranolol, bisoprolol, and pyridostigmine for postural tachycardia syndrome: a randomized clinical trial. Neurotherapeutics 15:785–95
    [Google Scholar]
  78. 78. 
    Raj SR, Black BK, Biaggioni I et al. 2009. Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: less is more. Circulation 120:725–34
    [Google Scholar]
  79. 79. 
    Zhao J, Du S, Yang J et al. 2014. Usefulness of plasma copeptin as a biomarker to predict the therapeutic effectiveness of metoprolol for postural tachycardia syndrome in children. Am. J. Cardiol. 114:601–5
    [Google Scholar]
  80. 80. 
    Raj SR, Black BK, Biaggioni I et al. 2005. Acetylcholinesterase inhibition improves tachycardia in postural tachycardia syndrome. Circulation 111:2734–40
    [Google Scholar]
  81. 81. 
    Kanjwal K, Karabin B, Sheikh M et al. 2011. Pyridostigmine in the treatment of postural orthostatic tachycardia: a single-center experience. Pacing Clin. Electrophysiol. 34:750–55
    [Google Scholar]
  82. 82. 
    Singer W, Opfer-Gehrking TL, Nickander KK et al. 2006. Acetylcholinesterase inhibition in patients with orthostatic intolerance. J. Clin. Neurophysiol. 23:476–81
    [Google Scholar]
  83. 83. 
    Ruzieh M, Sirianni N, Ammari Z et al. 2017. Ivabradine in the treatment of postural tachycardia syndrome (POTS), a single center experience. Pacing Clin. Electrophysiol. 40:1242–45
    [Google Scholar]
  84. 84. 
    McDonald C, Frith J, Newton JL 2011. Single centre experience of ivabradine in postural orthostatic tachycardia syndrome. Europace 13:427–30
    [Google Scholar]
  85. 85. 
    Gee ME, Watkins AK, Brown JN et al. 2018. Ivabradine for the treatment of postural orthostatic tachycardia syndrome: a systematic review. Am. J. Cardiovasc. Drugs 18:195–204
    [Google Scholar]
  86. 86. 
    Gaffney FA, Lane LB, Pettinger W, Blomqvist CG 1983. Effects of long-term clonidine administration on the hemodynamic and neuroendocrine postural responses of patients with dysautonomia. Chest 83:436–38
    [Google Scholar]
  87. 87. 
    Kpaeyeh J Jr, Mar PL, Raj V et al. 2014. Hemodynamic profiles and tolerability of modafinil in the treatment of postural tachycardia syndrome: a randomized, placebo-controlled trial. J. Clin. Psychopharmacol. 34:738–41
    [Google Scholar]
  88. 88. 
    Joyner MJ, Masuki S. 2008. POTS versus deconditioning: the same or different?. Clin. Auton. Res. 18:300–7
    [Google Scholar]
/content/journals/10.1146/annurev-med-041818-011630
Loading
/content/journals/10.1146/annurev-med-041818-011630
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error